major thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: Intervention group1: Exjade
Novartis plant in France
tablets 20 mg per kg body weight
3 times a day for 6 months. Intervention 2: Intervention group2: Deferoxamine and Exjade
Deferoxamine subcutaneous 40 mg per kg of body weight and tablet Exjade dose of 10 mg per kg of body weight
Deferoxamine once a two days and tablet Exjade once a day for 6 month. Intervention 3: Control group:Deferoxamine
subcutaneous 40 mg per kg body weight
once daily for 6 months.
Treatment - Drugs
Intervention group1: Exjade
3 times a day for 6 months
Intervention group2: Deferoxamine and Exjade
Sponsors
Vice chancellor for research, Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Approved based on clinical symptoms and history of thalassemia and hemoglobin electrophoresis; full cooperation during the study; treatment with deferoxamine subcutaneous injection and ferritin levels below 3000. Exclusion criteria: Deferiprone gastrointestinal intolerance; leukocytes less than 3,000; severe liver disease; ascites; lack of consent, lack of cooperation in the history of previous treatment regimens (blood transfusion and deferoxamine).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ferritin level. Timepoint: Before the intervention; three months after the intervention and six months after intervention. Method of measurement: Based on the results of test ferritin. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Akramipour
Kermanshah university of medical sciences
Outcome results
None listed